An observational study in Lung Cancer, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by M.D. Anderson Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center — 22 open to participants now, 48 under way, 2 of them phase 3. Lung Neoplasms · M.D. Anderson Cancer Center.
Among the 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center, this one is the 24th largest by planned enrollment of the 37 observational ones that give a count, is one of 2 that started in 2025, is one of 37 observational ones, reaches primary completion later than 44 of the 47 other live ones, and was the 161st registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →22 of the 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
M.D. Anderson Cancer Center · Sites in United States
Ages 50–80 · Healthy volunteers
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 68 · Phase 3 6 · Phase 4 1
First in 1993; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is below the median of 200 across 1,436 observational studies indexed under Lung Neoplasms.
Median enrollment 40 across the 125 interventional studies, 127 across the 37 observational. Of the 99 that completed or were terminated, 38 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
20 of the studies in Lung Neoplasms by M.D. Anderson Cancer Center that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03637816Phase 3M.D. Anderson Cancer CenterAnamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | 2026-12-31 |
| NCT03391869Phase 3M.D. Anderson Cancer CenterNivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | 2027-03-31 |
| NCT02596490M.D. Anderson Cancer CenterCouple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners | 2026-12-01 |
| NCT04516070M.D. Anderson Cancer CenterStereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis | 2026-12-31 |
| NCT04771520M.D. Anderson Cancer CenterAvapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | 2026-12-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this research study is to learn about:
The effect of enrolling in the YOLC program on patient satisfaction with care provided,
The needs of patients younger than 50 with lung cancer and their family, and
The impact of participating in peer support networks on these patients.
Primary Objectives:
Secondary Objectives:
MD Anderson
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The following special patient population will be excluded from study group:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a registry trial enrolling participants with NSCLC diagnosed and histologically confirmed prior to the age of 50 years identified. Each participant will participate in an intake survey as well as periodic recurring surveys to provide feedback to the YOLC Program, to elucidate the individual participant's care needs, and to assess changes in personal goals, wellness, financial impact, and family support over time
Other: Survey
Participants will complete an intake survey and repeat surveys at the following time points: * Baseline * 3 months * 6 months * 9 months * 12 months * 18 months * 24 months * 36 months * 48 months * 60 months
Participant satisfaction with care
Assessed via validated survey instruments (e.g., FACT-L, COST-FACIT). • Focus on detecting even small changes in survey responses over time (baseline, 3, 6, 9, 12 months, etc.).
Time frame: Through study completion; an average of 5 year
Started Sep 2025 (actual). Primary completion is estimated for May 2029, 44 months after the start.
Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 44 months is below that.
Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.